AC Immune SA (ACIU) is a world-renowned clinical-stage biopharmaceutical firm specializing in precision medicine for neurological disorders, such as neurodegenerative and neuroinflammatory diseases. The company's approach is driven by a progressive understanding of genetic, epigenetic, and signal transduction cascades in these disorders. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune SA has spent nearly two decades pushing the boundaries of scientific research to combat complex neurological ailments.
The company's unique strategic approach is rooted in two propriety discovery platforms - SupraAntigenTM and MorphomerTM. These platforms are leveraged to design, discover, and develop groundbreaking therapies, biologics, and vaccines. The company has introduced a diverse pipeline of first-in-class products that have the potential to meaningfully improve the lives of patients suffering from devastating neurological diseases.
AC Immune SA is globally recognized for its disease-modifying treatments targeting critical proteins involved in neurodegeneration, such as Tau and alpha-synuclein. Its anti-Tau and anti-amyloid beta antibodies are some of the most advanced in Alzheimer's disease (AD). The company's Tau-targeted therapies are especially significant, with the scientific community recognizing Tau pathology as a crucial driver of disease progression in AD and other neurodegenerative disorders.
One of AC Immune SA's notable collaborations is with Eli Lilly and Company for the development and potential commercialization of the anti-Tau antibody, semorinemab, in AD. Additionally, a partnership with Roche, namely Genentech, for the anti-Abeta antibody, crenezumab, has yielded promising results. Both partnerships signify the mutual efforts of big pharmaceutical companies and scientific innovators like AC Immune SA to lead the fight against neurological diseases.
Over the years, AC Immune SA has shown relentless dedication to their mission of combating neurological diseases. Besides corporate collaborations, the company actively participates in clinical studies globally, supporting their drug candidates in various phases of clinical trials.
While remaining at the forefront of scientific discovery, AC Immune SA also maintains a strong commitment to corporate transparency and responsible corporate citizenship. The company continuously updates its shareholders and the investment community about its consistent progress and future pathway.
As biopharmaceutical science advances, AC Immune SA’s commitment to usher in a new era of therapeutics for neurological disorders only strengthens. The company continues to make significant strides in its pursuit of successful treatment and prevention strategies for neurodegenerative and neuroinflammatory diseases, thereby placing it as a key player in this crucial area of medicine.